For humans, drug doses are based largely on body weight. But in animals, differences in brain and body chemistry make the calculations far more complicated.
Integrating several tests into a SAR, scientists have identified the compound 2C-H as a structural basis of the anti-inflammatory response in rats.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
“In the pharmaceutical drug development community, this is what you dream about.”
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
The Miller School of Medicine is Studying CBD + Psilocybin for Treating Traumatic Brain Injury and PTSD
The University of Miami medical school study is funded by a $1.624 million grant from Tassili Life Sciences.